{
  "cancer_immunometabolic_markers": {
    "immune_checkpoint": [
      "PDCD1",
      "LAG3", 
      "CTLA4",
      "CD274",
      "HAVCR2",
      "TIGIT"
    ],
    "metabolic_drivers": [
      "KRAS",
      "LDHA",
      "CPT1A",
      "FABP4",
      "HK2",
      "PKM",
      "GLUT1",
      "SLC2A1"
    ],
    "warburg_effect": [
      "LDHA",
      "HK2",
      "PDK1",
      "PFKFB3",
      "ENO1",
      "PKM"
    ],
    "inflammatory": [
      "IL6",
      "TNF",
      "STAT3",
      "NFKB1",
      "CXCL8",
      "IL1B"
    ],
    "immunosuppressive": [
      "ARG1",
      "IDO1",
      "TDO2",
      "CD274",
      "VEGFA"
    ],
    "hypoxia": [
      "HIF1A",
      "VEGFA",
      "CA9",
      "BNIP3",
      "SLC2A1"
    ]
  },
  "dnb_thresholds": {
    "critical_transition": 3.0,
    "warning": 2.0,
    "watch": 1.5
  },
  "dii_thresholds": {
    "critical": 0.7,
    "elevated": 0.5,
    "normal": 0.3
  },
  "intervention_triggers": {
    "monotherapy_to_dual": {
      "dii_threshold": 0.6,
      "description": "Transition from monotherapy to dual therapy (e.g., LDHA inhibitor + anti-PD-1)"
    },
    "early_intervention": {
      "dii_threshold": 0.4,
      "description": "Initiate early intervention protocols"
    }
  },
  "validated_cancer_types": [
    "PAAD",
    "OV",
    "BRCA",
    "LUAD",
    "COAD"
  ],
  "reference": {
    "patent": "U.S. Provisional Application No. 63/968,064",
    "title": "Systems and Methods for Predicting and Controlling Physiological Collapse Using Dynamical Biomarker Indices",
    "filed": "2026-01-26"
  }
}
